Esperion Therapeutics, Inc.
$3.14
+0.32%Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -33.9).
Valuation inputs: P/E -33.9, earnings yield N/A, momentum +0.3%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is strong (ROE +7.5%, ROIC +23.7%).
Profitability stack: net margin -5.6%, ROE +7.5%, ROIC +23.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +164.8%, momentum +0.3%, net margin -5.6%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Esperion Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Esperion Therapeutics, Inc. Fair Value Envelope
Esperion Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Esperion Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Esperion Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Strong liquidity. The company has adequate resources to meet short-term liabilities.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Esperion Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that ESPR stock may experience modest gains over the coming 12 months. The consensus 1-year price target stands at 3.19, with estimates ranging from a low of 3.16 to a high of 3.28.
The consensus 1-year price target stands at 3.19, with estimates ranging from a low of 3.16 to a high of 3.28.
Analyst Consensus Analysis
Upside Potential
Fair value territory. Stock trading near consensus target suggests limited near-term catalysts. Focus on fundamental developments.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Efficient pricing: Stock trading at fair value with strong consensus suggests market has priced in expectations. Look for fundamental inflection points or new catalysts to drive meaningful moves.
Esperion Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $40K and sold $453K worth of ESPR shares, resulting in $413K of net selling activity.
3 Months
0
0.00
37.7K
102.35K
-102K
-$102K
3-6 Months
0
0.00
63.8K
232.87K
-233K
-$233K
6-9 Months
0
0.00
41.7K
116.61K
-117K
-$117K
9-12 Months
40.0K
40.00K
1.3K
1.48K
+39K
+$39K
Top Buyers
Thompson John Craig
Director
$40K
Top Sellers
Koenig Sheldon L.
Director, Officer: President And Ceo
$326K
Halladay Benjamin
Officer: Chief Financial Officer
$64K
Looker Benjamin
Officer: Chief Legal Officer
$63K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $413K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
ESPR has not reported any dividend yield values in the available annual periods.
espr Dividend History
Learning Layer
Related Guides
Build conviction on ESPR by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.